|
| Press Releases |
|
 |
|
| Tuesday, July 14, 2020 |
|
|
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease |
| The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. more info >> |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
| Wednesday, July 8, 2020 |
|
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
| Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
| Monday, July 6, 2020 |
|
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan |
| Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. more info >> |
|
|
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID |
| The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. more info >> |
|
| Thursday, June 25, 2020 |
|
|
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea |
| Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Buy International Homes at the Global Property Expo, Singapore
Jul 14, 2025 14:48 HKT/SGT
|
|
|
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
|
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
|
|
|
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering
Jul 11, 2025 08:28 HKT/SGT
|
|
|
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation 
Jul 11, 2025 07:00 HKT/SGT
|
|
|
XDS Datacentres and ICS Arabia partner to launch landmark 10MW Immersive Cooling Data Center in KSA
Jul 11, 2025 06:00 HKT/SGT
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 15:12 HKT/SGT
|
|
|
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA
Jul 10, 2025 12:30 HKT/SGT
|
|
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
